Company news

Oryzon Genomics SA news in 2019

Oryzon Genomics SA's news releases, calls and decks from 2019, newest first.

View company

ORYZON Presents New Efficacy Data From its Phase II Trial ALICE Investigating iadademstat in AML

December 9, 2019

ORYZON Reports Financial Results and Provides Corporate Update for the Third Quarter Ended September 30, 2019

October 28, 2019

ORYZON Presents New Positive REIMAGINE Efficacy Data of Vafidemstat in the Treatment of Aggression

October 3, 2019

ORYZON Presents Positive Efficacy Results on Iadademstat in ED-SCLC Patients at ESMO-2019

September 30, 2019

ORYZON Presents New Positive Efficacy Data on Vafidemstat for Treatment of Aggression

September 10, 2019

ORYZON’s Iadademstat Shows Efficacy Signs in Relapsed SCLC

September 9, 2019

ORYZON Reports Financial Results and Corporate Update for the First Half Ended June 30, 2019

July 30, 2019

ORYZON Announces End of Patient Recruitment for its Phase IIa Trials in Aggression with Vafidemstat: REIMAGINE and REIMAGINE-AD

July 29, 2019

ORYZON Raises Its Share Capital by EUR 20 Million Through a Private Placement

July 25, 2019

ORYZON Presents Data From ETHERAL Phase IIa Trial at the 2019 Alzheimer's Association International Conference in Los Angeles

July 16, 2019

ORYZON to Present Data From ETHERAL Phase IIa Trial at the 2019 Alzheimer's Association International Conference in Los Angeles

July 10, 2019

ORYZON Presents Preliminary Dose Finding Results of Phase II Trial With Iadademstat in AML

June 14, 2019

Decks in 2019